PsyRx Overview
PsyRx is a pharmaceutical R&D company developing biological API psilocybin and ibogaine in accordance with GMP standards. Using biological bioreactor technology, the company is focused on becoming a leading producer of GMP-standard ibogaine and psilocybin for use by target customers in the development and production of psychedelic- and ibogaine-based pharmaceuticals, food supplements, and other products. PsyRx also aims to develop a revolutionary antidepressant drug based on a combination of ibogaine and existing approved antidepressants, with a focus on reducing side effects and improving efficacy. The companys vision is to develop new drugs for the treatment of depression and addiction by using existing regulatory-approved antidepressant drug formulations with ibogaine. Ibogaine is also known to affect the brain much like antidepressants, but through different pathways. Therefore, PsyRx believes that there might be synergy between these two drugs, enabling them to treat depression with better efficacy and fewer side effects than existing antidepressants.
Cumulative Funding Raised Over Time ($)
$550KAug 2022
$2.0MDec 2020
$2.4MJul 2023
Latest News
Growth-Positive
PSYRX'S INNOVATIVE NEXT-GENERATION- PLANT-BASED SOLUTION FOR DEPRESSION
PsyRx, a Rehovot-based company, is developing natural pharmaceutical-grade psychedelics for mental health therapeutics. The company is working on a medication that combines ibogaine, a substance derived from the Tabernanthe Iboga plant, with an approved SSRI anti-depressant. The company believes this combination will be more effective and have fewer side effects than existing antidepressants. PsyRx is also investigating the therapeutic potential of psilocybin, sourced from hallucinogenic mushrooms. The company is currently conducting a Series C financing round through the online equity-based crowd-investing platform ExitValley, with TrippyVC being a major investor.
InvestmentExpand
growth-positive
PsyRx Announces Appointment of Prof. Itamar Grotto as New Executive Chairman of the Board
PsyRx Ltd, a pharmaceutical company specializing in drug discovery for mental health conditions, has appointed Professor Itamar Grotto as its Executive Chairman. This follows the recent renewal of the companys license to conduct R&D in Psilocybin and Ibogaine by the Israeli Ministry of Health. Prof. Grotto, a Public Health Physician and Professor of Epidemiology, has previously served as the Director of Public Health Services and the Associate Director General at the Israeli Ministry of Health. He was also a member of the Executive Board of the World Health Organization.
Management Changes
growth-positive
https://www.jpost.com/health-and-wellness/mind-and-spirit/article-695925
PsyRx, an Israel-based pharmaceutical company, has announced the appointment of Prof. Itamar Grotto as the new Executive Chairman of their scientific advisory board. Prof. Grotto was the former Associate Director-General of the Health Ministry between 2017 and 2021, a Public Health Physician and Professor of Epidemiology, and a WHO Executive Board Member. The company focuses on treating mental health conditions by producing and researching GMP-grade Psilocybin and Ibogaine for drug purposes.
Management Changes
growth-positive
Now psychedelics are coming to your medicine cabinet
PsyRx, an Israeli company, is developing standardized pharma-grade psychedelics from natural sources to treat mental health issues. The company uses an agro-medical bioreactor to produce psychedelic botanic extracts psilocybin and ibogaine, which have shown positive effects in treating depression, anxiety, addiction, and other conditions. PsyRx is focusing on the potential of ibogaine to improve current SSRI antidepressants. The company is planning to start small animal trials soon to check safety and efficacy, with hopes to start human trials in a year. PsyRx has raised a couple of million dollars from private investors and plans to go public.
InvestmentExpand
growth-positive
חברה ישראלית מפתחת תרופות חדשות לטיפול בדיכאון עם מרכיב מפתיע
Israeli company PsyRx is developing innovative drugs for the treatment of depression and addiction. The companys vision is to develop a new drug composed of a combination of an existing drug with extracts from mushrooms and the root of the iboga plant. The company is working on the development of intellectual property of growth and extraction methods of the iboga root and psilocybin, for use as raw materials in drugs through bio-reactors. The company initially will only produce the raw materials for other companies that will register the products as drugs. The process is in its most advanced stages and has even received significant financial investment.
Investment
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $2.38M |
| Last funding | $330K |
| Stage | Seed |
| Rounds | 3 |
| Investors | 0 |
Team Members
5
Employees: 1-10
Web & Social Links
| Website | www.psyrx.co/ |
Locations
Tel Aviv, Israel
Photos & Videos
1 item(s)
PsyRx Business
Business models
B2B
Product stage
Clinical Trial
Employees
1-10
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & DevelopmentTarget Customer
Healthcare & Life SciencesLife SciencesPharmaceuticalsCore Technology
BiologicalsHerbalsTags (6)
mental-healthpharma-companiestreatmentspharmaceuticalsfood-industrydrug-developmentPsyRx Financials
$2.38M
Total funding
Undisclosed
Capital raised
$330K
Last funding
Seed
Funding stage
3
Total rounds
0
Investors
Cumulative Funding Raised Over Time ($)
$550KAug 2022
$2.0MDec 2020
$2.4MJul 2023
Private Equity Funding
Seed
Jul 2023
$330K
Seed
Aug 2022
$550K
Pre-Seed
Dec 2020
$1.5M
PsyRx Lifecycle
Cumulative Funding Raised Over Time
$550KAug 2022
$2.0MDec 2020
$2.4MJul 2023
All Events
Seed
Jul 2023
$330K
Seed
Aug 2022
$550K
Pre-Seed
Dec 2020
$1.5M
PsyRx News
6 articles
Growth-Positive
PSYRX'S INNOVATIVE NEXT-GENERATION- PLANT-BASED SOLUTION FOR DEPRESSION
PsyRx, a Rehovot-based company, is developing natural pharmaceutical-grade psychedelics for mental health therapeutics. The company is working on a medication that combines ibogaine, a substance derived from the Tabernanthe Iboga plant, with an approved SSRI anti-depressant. The company believes this combination will be more effective and have fewer side effects than existing antidepressants. PsyRx is also investigating the therapeutic potential of psilocybin, sourced from hallucinogenic mushrooms. The company is currently conducting a Series C financing round through the online equity-based crowd-investing platform ExitValley, with TrippyVC being a major investor.
InvestmentExpand
growth-positive
PsyRx Announces Appointment of Prof. Itamar Grotto as New Executive Chairman of the Board
PsyRx Ltd, a pharmaceutical company specializing in drug discovery for mental health conditions, has appointed Professor Itamar Grotto as its Executive Chairman. This follows the recent renewal of the companys license to conduct R&D in Psilocybin and Ibogaine by the Israeli Ministry of Health. Prof. Grotto, a Public Health Physician and Professor of Epidemiology, has previously served as the Director of Public Health Services and the Associate Director General at the Israeli Ministry of Health. He was also a member of the Executive Board of the World Health Organization.
Management Changes
growth-positive
https://www.jpost.com/health-and-wellness/mind-and-spirit/article-695925
PsyRx, an Israel-based pharmaceutical company, has announced the appointment of Prof. Itamar Grotto as the new Executive Chairman of their scientific advisory board. Prof. Grotto was the former Associate Director-General of the Health Ministry between 2017 and 2021, a Public Health Physician and Professor of Epidemiology, and a WHO Executive Board Member. The company focuses on treating mental health conditions by producing and researching GMP-grade Psilocybin and Ibogaine for drug purposes.
Management Changes
growth-positive
Now psychedelics are coming to your medicine cabinet
PsyRx, an Israeli company, is developing standardized pharma-grade psychedelics from natural sources to treat mental health issues. The company uses an agro-medical bioreactor to produce psychedelic botanic extracts psilocybin and ibogaine, which have shown positive effects in treating depression, anxiety, addiction, and other conditions. PsyRx is focusing on the potential of ibogaine to improve current SSRI antidepressants. The company is planning to start small animal trials soon to check safety and efficacy, with hopes to start human trials in a year. PsyRx has raised a couple of million dollars from private investors and plans to go public.
InvestmentExpand
growth-positive
חברה ישראלית מפתחת תרופות חדשות לטיפול בדיכאון עם מרכיב מפתיע
Israeli company PsyRx is developing innovative drugs for the treatment of depression and addiction. The companys vision is to develop a new drug composed of a combination of an existing drug with extracts from mushrooms and the root of the iboga plant. The company is working on the development of intellectual property of growth and extraction methods of the iboga root and psilocybin, for use as raw materials in drugs through bio-reactors. The company initially will only produce the raw materials for other companies that will register the products as drugs. The process is in its most advanced stages and has even received significant financial investment.
Investment
growth-positive
https://www.jpost.com/health-science/israeli-lab-grows-magic-mushrooms-to-treat-depression-673524
Israeli pharmaceutical R&D company, PsyRx, is developing psilocybin and other biological psychoactive compounds using biological bioreactor technology. The companys main focus is on depression and addiction treatment. It also manufactures high-standard ibogaine, a psychoactive alkaloid effective in reducing addiction severity. The companys bioreactor allows it to grow more sterile and consistent compounds than would be possible in nature. PsyRx has completed its initial goals of growing psilocybin on solid and liquid surfaces and has begun its prior-to-submission phase to the FDA for approval to test an Ibogaine-based micro-dosed antidepressant drug.
InvestmentExpand
PsyRx Team
Employee Info
| Employees (range) | 1-10 |
| Exact count | 5 |
| Team members | 5 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 9 classification IDs that could be used for matching.
PsyRx Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 99/100 |
| Missing | markets |
| BI Verification | Yotam Maman |
| Registrar ID | 516095668 |
| Phone | +972522988480 |
| Creator | Yanina Wainscheinker |
| Creator email | yanina.wain@gmail.com |
| Last updater | Matan Eblagon |
| Updater email | matane@sncentral.org |
| Last update | 2025-01-21T00:00:00.000Z |
| Created | 2021-07-01T00:00:00.000Z |
| Claimed | Yes |